医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NCKU, Duke University Researchers Successfully Implant a New Cardiac Assist Device on Calf

2013年10月29日 PM12:55
このエントリーをはてなブックマークに追加


 

TAINAN, Taiwan

The National Cheng Kung University Heart Science and Medical Devices Research Center (NCKU HSDMRC) and the Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC, USA, jointly carried out a cardiac assist device implantation on calf recently.

Roberto Manson and Mani Daneshmand from Cardiothoracic Surgery, Duke University Medical Center attended the workshop of Duke-NCKU collaboration on early interventional ventricular assist device hosted by NCKU, October 13-16, and participated in the para-aortic blood pump (PABP) implantation surgery on calf.

NCKU HSDMRC Director Pong-Jeu Lu, who is also a professor at the NCKU Department of Aeronautics and Astronautics, had led his research team to develop the PABP for over thirteen years.

He said, “PABP is a new type of left ventricular assist device which has completed major design, prototype manufacturing and testing after more than 10 years of effort.”

“This study could be extended to humans where clinical trials are to be conducted within the next two years, which will benefit more patients with heart failure in the future,” Manson noted.

“It is worthwhile mentioning that PABP is designed to be implanted in patients with heart failure prior to irreversible stage to hopefully restore heart function,” according to Lu.

However, the most important part would be the minimally invasive surgery, which allows rapid implantation into the aorta without affecting heart functions, thus shortening the recovery time after surgery.

Last year, Lu’s research team had signed a 3-year Agreement with the Division of Cadiothoracic Surgery, Department of Surgery at Duke University on the research development of cardiac assist device, efficacy and safety regarding surgical treatment on patients with heart failure and the pathway of cell recovery after long-term PABP support.

“NCKU’s PABP research outcome can be applied on patients with heart failure of non-refractory stage,” noted Daneshmand who was impressed by NCKU’s latest medical invention. He also added, “It can also be used to restore heart function of patients with late stage heart failure and prolong patient’s life with reasonable quality; hence it is a very advanced piece of medical innovation.”

Manson added, “It is an exciting result that the calf has strong heartbeat after surgery.” The research entering the phase of human trials within two years is foreseeable.

CONTACT

National Cheng Kung University
Sonia Chuang, +886-6-275-7575 ext.
50042
News Center
sonia20@mail.ncku.edu.tw

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作